Liver disease, particularly viral hepatitis, is increasingly common. The most frequent causes of long-term, or chronic, viral hepatitis are persistent infections with the hepatitis B or hepatitis C virus. Worldwide, 400 million people are chronic carriers of the hepatitis B virus [1]. Each year, between 500,000 to 1.2 million people die from progression of this viral infection, making it the 10...

Hepatitis B is a global acute and chronic life-threatening liver infection caused by the hepatitis virus. During cadaveric dissection, clinical rotations, autopsy posting, medical students get exposed to patients’ blood body fluids, which increases risk of infection. can be prevented vaccines that are safe, easily available, effective, however many still unvaccinated. This results in need for a...

OBJECTIVE Tumor necrosis factor-alpha (TNF-alpha) inhibitors have emerged as a potent treatment for rheumatoid arthritis (RA), but not without significant risks. In chronic hepatitis B viral infection TNF-alpha is readily produced, and viral clearance is dependent on the amount bioavailable. Limited data suggest that TNF-alpha inhibitors may facilitate uncontrolled hepatitis B viral replication...

Infection with hepatitis B virus can lead to serious long-term complications including chronic hepatitis B virus infection leading to hepatocellular carcinoma, liver failure, and death. We report a case of prolonged hepatitis B antigenemia after routine vaccination with Engerix B. A positive hepatitis B surface antigen was found when the individual donated blood 18 days after vaccination. This ...

DESCRIPTION Reaffirmation of the 2004 U.S. Preventive Services Task Force (USPSTF) recommendation on screening for hepatitis B virus hepatitis B virus infection in pregnancy. METHODS The USPSTF performed a brief literature update, including a search for new and substantial evidence on the benefits and harms of screening pregnant women for hepatitis B virus infection. FINDING The net benefit...

With up to 400 million affected people worldwide, chronic hepatitis B virus (HBV) infection is still a major health care problem. During the last decade, several novel therapeutic approaches have been developed and evaluated. In most regions of the world, interferon-α (IFN-α), and nucleos(t)ide analogues are currently approved. Despite major improvements, none of the existing therapies is optim...